JP Patent

JP2018517721A — 原発性巣状分節性糸球体硬化症を処置する方法

Assigned to Genzyme Corp · Expires 2018-07-05 · 8y expired

What this patent protects

ＴＧＦβアンタゴニストを患者に静脈内投与することを含む、ＡＰＯＬ１バリアントを有する患者において原発性巣状分節性糸球体硬化症を処置する方法。

USPTO Abstract

ＴＧＦβアンタゴニストを患者に静脈内投与することを含む、ＡＰＯＬ１バリアントを有する患者において原発性巣状分節性糸球体硬化症を処置する方法。

Drugs covered by this patent

atrasentan-hydrochloride (ATRASENTAN HYDROCHLORIDE)

Patent Metadata

Patent number: JP2018517721A
Jurisdiction: JP
Classification: —
Expires: 2018-07-05
Drug substance claim: No
Drug product claim: No
Assignee: Genzyme Corp
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.